These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18306373)

  • 1. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
    Watashi K; Metselaar HJ; van der Laan LJ
    Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
    [No Abstract]   [Full Text] [Related]  

  • 2. Review article: hepatitis C virus and calcineurin inhibition after renal transplantation.
    Fabrizi F; Bromberg J; Elli A; Dixit V; Martin P
    Aliment Pharmacol Ther; 2005 Oct; 22(8):657-66. PubMed ID: 16197487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient.
    Pollard S
    Liver Int; 2004 Oct; 24(5):402-6. PubMed ID: 15482334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection.
    Kneteman NM; Asthana S; Lewis J; Dibben C; Douglas D; Nourbakhsh M; Tyrrell LJ; Lund G
    Liver Transpl; 2012 Jan; 18(1):38-44. PubMed ID: 21837737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Of mice and men, calcineurin inhibitors and hepatitis C.
    Rutebemberwa A; Rosen HR
    Liver Transpl; 2012 Jan; 18(1):1-4. PubMed ID: 22034173
    [No Abstract]   [Full Text] [Related]  

  • 6. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3.
    Patel H; Heathcote EJ
    Gut; 2011 Jun; 60(6):879. PubMed ID: 20966029
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus dynamics in vivo and the antiviral efficacy of interferon alfa therapy.
    Thomas HC; Török ME; Foster GR
    Hepatology; 1999 Apr; 29(4):1333-4. PubMed ID: 10094985
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C virus kinetics in chimeric mice during antiviral therapy.
    Dahari H; Perelson AS
    Hepatology; 2007 Dec; 46(6):2048-9; author reply 2049-50. PubMed ID: 17935224
    [No Abstract]   [Full Text] [Related]  

  • 10. How does interferon inhibit HCV cell entry?
    Jones M; Owen JS
    Gut; 2008 May; 57(5):573-4. PubMed ID: 18408099
    [No Abstract]   [Full Text] [Related]  

  • 11. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.
    Duvoux C; Firpi R; Grazi GL; Levy G; Renner E; Villamil F
    Transpl Int; 2013 Apr; 26(4):358-72. PubMed ID: 23413991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C: infection and current treatment strategies.
    Piascik P
    J Am Pharm Assoc (Wash); 1997; NS37(4):376-8. PubMed ID: 9519644
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation.
    Fontana M; Ciuffreda D; Moradpour D; Pascual M
    Transplantation; 2007 Feb; 83(4):525-6. PubMed ID: 17318091
    [No Abstract]   [Full Text] [Related]  

  • 15. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha.
    Pan Q; Metselaar HJ; de Ruiter P; Kwekkeboom J; Tilanus HW; Janssen HL; van der Laan LJ
    Liver Transpl; 2010 Apr; 16(4):520-6. PubMed ID: 20373462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult hepatitis C: how convincing are the current data?
    Welker MW; Zeuzem S
    Hepatology; 2009 Feb; 49(2):665-75. PubMed ID: 19105211
    [No Abstract]   [Full Text] [Related]  

  • 18. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice.
    McHutchison JG; Bartenschlager R; Patel K; Pawlotsky JM
    J Hepatol; 2006 Feb; 44(2):411-21. PubMed ID: 16364491
    [No Abstract]   [Full Text] [Related]  

  • 19. The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.
    Garcia-Saenz-de-Sicilia M; Mukherjee S
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):587-93. PubMed ID: 23121280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does iron reduction improve sustained viral responses to interferon monotherapy in hepatitis C patients? Maybe, but is this the right question?
    Shedlofsky SI
    Am J Gastroenterol; 2002 May; 97(5):1093-6. PubMed ID: 12014712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.